Novan Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Novan stock.
View analyst ratings for Novan or view top-rated stocks.

Wall Street analysts have given Novan a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Novan wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Novan saw a drop in short interest during the month of May. As of May 28th, there was short interest totaling 306,500 shares, a drop of 87.5% from the May 13th total of 2,460,000 shares. Based on an average trading volume of 634,800 shares, the days-to-cover ratio is currently 0.5 days. Currently, 2.1% of the company's shares are short sold.
View Novan's Short Interest.

Novan is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Novan.

Novan, Inc. (NASDAQ:NOVN) issued its earnings results on Tuesday, May, 11th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The firm had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.96 million. Novan had a negative net margin of 708.75% and a negative trailing twelve-month return on equity of 1,050.18%.
View Novan's earnings history.

Novan's stock was trading at $0.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NOVN stock has increased by 1,930.8% and is now trading at $10.56.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued 12 month target prices for Novan's shares. Their forecasts range from $2.00 to $3.00. On average, they expect Novan's share price to reach $2.50 in the next year. This suggests that the stock has a possible downside of 76.3%.
View analysts' price targets for Novan or view top-rated stocks among Wall Street analysts.

Some companies that are related to Novan include Spectrum Pharmaceuticals (SPPI), Akebia Therapeutics (AKBA), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Altimmune (ALT), Adagene (ADAG), Catalyst Pharmaceuticals (CPRX), AC Immune (ACIU), ZIOPHARM Oncology (ZIOP), Bolt Biotherapeutics (BOLT), Annovis Bio (ANVS), Vaccitech (VACC), Citius Pharmaceuticals (CTXR), Eagle Pharmaceuticals (EGRX) and Relmada Therapeutics (RLMD).
View all of NOVN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), ADMA Biologics (ADMA), Cannabics Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL) and OrganiGram (OGI).

(NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Novan trades on the NASDAQ under the ticker symbol "NOVN."

Novan's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.76%), Renaissance Technologies LLC (1.20%), Geode Capital Management LLC (0.78%), Millennium Management LLC (0.73%), Northern Trust Corp (0.20%) and Morgan Stanley (0.17%). Company insiders that own Novan stock include Life Sciences Holdings L Malin and Paula B Stafford.
View institutional ownership trends for Novan.

NOVN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..
View insider buying and selling activity for Novan or view top insider-selling stocks.

NOVN stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Citadel Advisors LLC, Geode Capital Management LLC, Squarepoint Ops LLC, Edmond DE Rothschild Holding S.A., Price T Rowe Associates Inc. MD, and Bank of New York Mellon Corp.
View insider buying and selling activity for Novan or or view top insider-buying stocks.

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NOVN stock can currently be purchased for approximately $10.56.

Novan has a market capitalization of $160.21 million and generates $4.92 million in revenue each year. The company earns $-29,290,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

Novan employs 23 workers across the globe.

The official website for Novan is www.novan.com.

Novan is headquartered at 4105 HOPSON ROAD, MORRISVILLE NC, 27560.

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at (919) 485-8080 or via email at [email protected]